ArticlePituitary2023
Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre.
Article in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Addison's disease in Italy: mortality and survival by etiology.Journal of endocrinological investigation · 2026Article
- Fournier gangrene in a patient with corticotrophinoma and diabetes treated with sodium-glucose cotransporter 2 inhibitor.JCEM case reports · 2026Article
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews · 2026Review
- Use of osilodrostat in a block-and-replace and titration strategy for cushing's syndrome: a position paper by French experts.Reviews in endocrine & metabolic disorders · 2026Article
- Impact of sex on mortality in patients with pituitary adenomas.Pituitary · 2026Review
- Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- European survey on metabolic and cardiovascular risk in Cushing syndrome.Journal of endocrinological investigation · 2025Article
- Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level.Endocrine journal · 2025Article
- Article
- PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.Endocrine · 2025Article
- Cardiometabolic complications after Cushing's disease remission.Journal of endocrinological investigation · 2025Observational
- Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.Journal of the Endocrine Society · 2025Article
- Unusual infections and thrombotic events in Cushing's syndrome.Journal of endocrinological investigation · 2025Review
- Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations.Journal of the Endocrine Society · 2025Review
- Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study.Endocrine · 2025Article
- Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.Pituitary · 2025Article
- Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis.Pituitary · 2024Article
- Article
- Diagnostic dilemma in Cushing's syndrome: discrepancy between patient-reported and physician-assessed manifestations.Endocrine · 2024Article
- Insights on epidemiology, morbidity and mortality of Cushing's disease in Northern Ireland.Endocrine-related cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextCushing's disease (CD) is rare condition burdened by several systemic complications correlated to higher mortality rates. The primary goal of clinicians is to achieve remission, but it is unclear if treatment can also increase life expectancy.
aimTo assess the prevalence of cortisol-related complications and mortality in a large cohort of CD patients attending a single referral centre. MATERIALS AND
methodsThe clinical charts of CD patients attending a referral hospital between 2001 and 2021 were reviewed.
results126 CD patients (median age at diagnosis 39 years) were included. At the last examination, 78/126 (61.9%) of the patients were in remission regardless of previous treatment strategies. Patients in remission showed a significant improvement in all the cardiovascular (CV) comorbidities (p < 0.05). The CV events were more frequent in older patients (p = 0.003), smokers and persistent CD groups (p < 0.05). Most of the thromboembolic (TE) and infective events occurred during active stages of the disease. The CV events were the most frequent cause of death. The standardized mortality ratio (SMR) resulted increased in persistent cases at the last follow-up (SMR 4.99, 95%CI [2.15; 9.83], p < 0.001) whilst it was not higher in those in remission (SMR 1.66, 95%CI [0.34; 4.85], p = 0.543) regardless of the timing or number of treatments carried out. A younger age at diagnosis (p = 0.005), a microadenoma (p = 0.002), and remission status at the last follow-up (p = 0.027) all increased survival. Furthermore, an elevated number of comorbidities, in particular arterial hypertension, increased mortality rates.
conclusionsPatients with active CD presented a poor survival outcome. Remission restored the patients' life expectancy regardless of the timing or the types of treatments used to achieve it. Persistent CD-related comorbidities remained major risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.